Talis Biomedical Corporation (TLIS) 2022年年度报告「NASDAQ」.pdf

1、 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2022OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934 FOR THE TRANSITION PERIOD FROM TOCommission File Number:001-40047 Talis Biomedical Corporation(Exact name of Registrant as specified in its Charter)Delaware(State or other jurisdiction ofincorporation or organization)46-3122255(I.R.S.EmployerIdentification No.)3400 Bridge ParkwayRedwood City

3、,California 94065(Address of principal executive offices)(Zip Code)(650)433-3000 (Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class TradingSymbol(s)Name of each exchange on which registeredCommon Stock,$0.0001 par value per

4、 share TLIS The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.YES NO Indicate by check mark if the Registrant is not required to file reports

5、pursuant to Section 13 or 15(d)of the Act.YES NO Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the Registrant was required to file

6、 such reports),and(2)has been subject to such filing requirements for the past 90 days.YES NO Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the prec